<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710801</url>
  </required_header>
  <id_info>
    <org_study_id>COLO400A2427</org_study_id>
    <nct_id>NCT00710801</nct_id>
  </id_info>
  <brief_title>Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation</brief_title>
  <official_title>Randomized, Open-label Study to Evaluate the Hepatitis C Virus (HCV) Burden in Patients Receiving Cyclosporine (Neoral or CSA) Versus Tacrolimus (Prograf) in de Novo Liver Recipients Receiving Mycophenolate Sodium (Myfortic): Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about how different immunosuppressant therapies impact&#xD;
      on recurrent hepatitis C virus infection in the new liver after liver transplant. We will be&#xD;
      evaluating if Cyclosporin A has a superior effect against recurrent Hepatitis C virus (HCV)&#xD;
      infection than Tacrolimus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will address the hypothesis that CSA has a superior antiviral effect against HCV than&#xD;
      Tacrolimus by assessing serial HCV RNA levels in serum. We plan to address the hypothesis&#xD;
      that CSA is more efficient in limiting viremia than Tacrolimus and that viremia is predictive&#xD;
      of long-term clinical outcome of hepatic fibrosis that is known to impact on both graft and&#xD;
      patient survival&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C Virus</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HCV positive patients undergoing orthotopic liver transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  About to undergo a primary liver transplant (including living donor, split liver) and&#xD;
             are HCV positive.&#xD;
&#xD;
          -  Willing and capable of giving written consent for study participation&#xD;
&#xD;
          -  Expected to be capable of study participation for full 24 months post-transplantation.&#xD;
&#xD;
          -  Allograft biopsies will be possible&#xD;
&#xD;
          -  Expected use of calcineurin inhibitor (Neoral or Tacrolimus) as primary&#xD;
             immunosuppression An immunosuppressive regimen consisting of a calcineurin inhibitor&#xD;
             (Neoral or Tacrolimus) in combination with Simulect and MYCOPHENOLATE SODIUM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  This is a multi-organ transplant or if the patient has previously been transplanted&#xD;
             with any other organ.&#xD;
&#xD;
          -  This is a liver transplant from a non-heart beating donor.&#xD;
&#xD;
          -  This is an ABO incompatible transplant.&#xD;
&#xD;
          -  Patients with serum creatinine level &gt; 250 umol/L.&#xD;
&#xD;
          -  The recipient is seropositive for human immunodeficiency virus (HIV) antibodies.&#xD;
&#xD;
          -  Fulminant liver failure is the reason for transplant.&#xD;
&#xD;
          -  Patient is participating in other clinical trial involving exploratory drug&#xD;
&#xD;
          -  There is a known malignancy, or a history of malignancy, other than successfully&#xD;
             treated non-metastatic basal or squamous cell carcinoma of the skin, or hepatocellular&#xD;
             carcinoma less than 5 cm meeting Milan criteria for transplantation5.&#xD;
&#xD;
          -  The patient is being transplanted for hepatic malignancy with greater than 5 known&#xD;
             lesions.&#xD;
&#xD;
          -  Severe coexisting disease is present or if any unstable medical condition is present&#xD;
             which could affect the study objectives.&#xD;
&#xD;
          -  A female transplant candidate is pregnant, lactating or of childbearing potential and&#xD;
             not practicing an acceptable method of contraception.&#xD;
&#xD;
          -  An unlicensed drug or therapy has been administered within one month prior to study&#xD;
             entry or if such therapy is to be instituted post-transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew L Mason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>September 14, 2011</last_update_submitted>
  <last_update_submitted_qc>September 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>HCV</keyword>
  <keyword>Liver Transplant</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Myfortic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

